CLINICAL TRIALS PROFILE FOR BELZUTIFAN
✉ Email this page to a colleague
All Clinical Trials for Belzutifan
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT02974738 ↗ | A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) | Active, not recruiting | Peloton Therapeutics, Inc. | Phase 1 | 2016-12-07 | The primary objective of this study is to identify the maximum tolerated dose (MTD) of belzutifan Tablets and/or the recommended Phase 2 dose (RP2D) of belzutifan Tablets in patients with advanced solid tumors |
NCT03401788 ↗ | A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004) | Active, not recruiting | Peloton Therapeutics, Inc. | Phase 2 | 2018-05-02 | This study is designed to investigate belzutifan as a treatment for VHL disease associated RCC. |
NCT03445169 ↗ | A Food Effect Study in Healthy Volunteers With Belzutifan (PT2977, MK-6482) Tablets | Completed | Peloton Therapeutics, Inc. | Phase 1 | 2018-02-23 | This Phase 1, single-dose study will be conducted in adult male and female subjects (N = 16) who are in general good health and selected for participation in the study according to the selection criteria. This study will assess the effect of food on the pharmacokinetics of belzutifan Tablets. The study will consist of two periods and will be conducted in a crossover fashion. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Belzutifan
Condition Name
Clinical Trial Locations for Belzutifan
Trials by Country
Clinical Trial Progress for Belzutifan
Clinical Trial Phase
Clinical Trial Sponsors for Belzutifan
Sponsor Name